A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study
| Autor: | Giuseppe Comella, Pasquale Comella, Cosimo Brunetti, Giuseppe Frasci, Ignazio Carreca, Sergio Palmeri, D. Muci, G DeCataldis, Antonio Russo, G.P. Nicolella, N. Panza, Michele Di Natale, Francovito Piantedosi |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Neutropenia Paclitaxel medicine.medical_treatment Phases of clinical research Gastroenterology Small-cell carcinoma Disease-Free Survival Drug Administration Schedule topotecan Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Carcinoma Small Cell Aged Cisplatin Chemotherapy business.industry Regular Article Middle Aged medicine.disease Thrombocytopenia Granulocyte colony-stimulating factor Surgery Regimen weekly chemotherapy Oncology Female Taxoids Topotecan small cell lung cancer business medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 |
| Popis: | The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2weekly, with G-CSF (5 μg/kg days 3–5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% CI = 65–92%] ORR. At a 13-month (range, 4–26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches. © 2001 Cancer Research Campaign http://www.bjcancer.com |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|